Anavex Life Sciences Corp (AVXL)

[falconer66a]

No Amyloid Pre-Selling Required

SAVA is not pursuing amyloid yet got lots of attention and huge stock price boost.

Well, of course not. At the start, everyone in the Alzheimer's business knew with scholarly certainty that beta-amyloids had to be the therapeutic target. All SAVA had to claim was that its new drug was able to able to reduce amyloid concentrations. 'Nuff said. Fitted perfectly with everything already 'known.'

Conventional stock investors said, "Hey, finally, here it is! This is The One; it takes on the amyloids. Gotta get me some SAVAs."

Dollars went in that direction. There didn't need to be any amyloid pre-selling; it was in place --- and until the Anavex clinical results appear, will continue.